CLINICAL & PIPELINE·Drug Approval
Hospira's Morphine Sulfate: 2020 Labeling Approval Reinforces Ongoing Regulatory Compliance for Generic Analgesics
Hospira, Inc. received a U.S. Food and Drug Administration (FDA) supplemental approval on February 10, 2020, for a labeling update to its generic Morphine Sulfate injectable (ANDA073509). This regulatory action for the long-standing analgesic, originally approved in 1992, underscores ongoing compliance requirements for mature pharmaceutical products. Decision-makers must recognize the continuous need for robust regulatory affairs and supply chain management to maintain market access and product integrity.
90-Day Activity